-
2022-501217-31-00
10
2023-03-09
Hepatocellular carcinoma
-
2023-509494-23-00
4
2023-02-20
Adult patients with intermediate unfavorable risk prostate cancer as p
-
2024-516168-27-00
5
2022-11-10
Adult patients with persistent or chronic immune thrombocytopenia
-
2024-517024-20-00
9
2022-09-27
Metastatic colorectal cancer patients
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2024-512634-15-00
9
2022-01-05
Patients with untreated mantle cell lymphoma
-
2023-507286-25-00
4
2021-12-23
Diffuse Large B-Cell Lymphoma
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-509120-17-00
5
2021-04-12
Myelofibrosis
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer